Seeking Alpha
 

BioMimetic Therapeutics, Inc. (BMTI)

- NASDAQ
BMTI is defunct.
  • Mar. 1, 2013, 1:29 PM
    Wright Medical Group (WMGI +1.2%) says it's completed its acquisition of BioMimetic Therapeutics (BMTI). WMGI acquired BioMimetic for an upfront purchase price of approximately $190M in cash and stock plus additional milestone payments of up to approximately $190M in cash, which are payable upon receipt of FDA approval of its Augment Bone Graft and upon achieving certain revenue milestones.
    | Mar. 1, 2013, 1:29 PM | Comment!
  • Nov. 19, 2012, 12:45 PM
    Midday top 10 gainers: BMTI +72%. SAB +65%. GTIM +48%. TRT +19%. OCLR +14%. ASUR +13%. LGND +13%. BGCP +13%. CEDC +12%. MHR +12%. Midday top 10 Losers: SGOC -14%. BSPM -12%. TSTC -12%. LRN -12%. ALDA -11%. DMND -12%. MLP -10%. ACTG -10%. MSB -10%. NOAH -9%.
    | Nov. 19, 2012, 12:45 PM | Comment!
  • Nov. 19, 2012, 9:10 AM
    Premarket gainers: BMTI +77%. INVE +12%. ALXA +9%. SINA +8%. JRCC +7%. PCS +7%. STSI +6%. LOW +6%. DDD +6%
    | Nov. 19, 2012, 9:10 AM | Comment!
  • Nov. 19, 2012, 8:02 AM
    Orthopedics company Wright Medical (WMGI) agrees to acquire BioMimetic Therapeutics (BMTI) for up to $380M in cash and shares. Wright will pay an initial $190M, with the rest to be based on FDA approval of BioMimetic's Augment Bone Graft and revenue milestones. The total deal values BioMimetic at up to $12.97 a share vs its Friday close of $4.15. BMTI +82% premarket at $7.55. (PR)
    | Nov. 19, 2012, 8:02 AM | Comment!
  • Jul. 10, 2012, 10:29 AM
    BioMimetic Therapeutics (BMTI) soars 16.1% after submitting more information to the FDA about its Augment treatment, saying that the bone-graft product is not inferior to autograft. The agency decided not to OK Augment in January, when it asked for the additional data. BioMimetic now expects a decision on approval next year or in early 2014. (PR)
    | Jul. 10, 2012, 10:29 AM | Comment!
  • Feb. 7, 2012, 3:29 PM
    BioMimetic Therapeutics (BMTI +12.2%) soars a day after reporting positive data from a small trial testing its augment bone graft device in patients undergoing surgery for rotator cuff injuries. The FDA last month declined to approve the graft and sought more data, but the new information boosts hopes of attracting interest from potential partners.
    | Feb. 7, 2012, 3:29 PM | Comment!
  • Jan. 3, 2012, 7:13 PM
    BioMimetic Therapeutics (BMTI) tanks in the post-trading session after the FDA says its proposed bone-graft device, Augment, wouldn't be approved without more information from previous studies. The company says it plans to submit the necessary information by the middle of the year. Shares -10.7% AH.
    | Jan. 3, 2012, 7:13 PM | Comment!
  • May 13, 2011, 9:00 AM
    Premarket gainers: DDS +13%. BMTI +13%. RIC +9%. A +8%. EK +7%. TYC +7%. DF +6%. LPL +5%. CTIC +4%. BPAX +3%.
    Losers: NVDA -7%. YHOO -5%. EPB -4%. AIS -4%. LXP -3%.
    | May 13, 2011, 9:00 AM | 1 Comment
  • May 10, 2011, 9:00 AM
    Premarket gainers: DF +10%. EGHT +5%. VG +4%. EBAY +3%. NXG +3%. ING +3%.
    Losers: BMTI -28%. MKND -14%. PAL -6%. DHX -6%. GMXR -6%. MOTR -4%. CNK -3%.
    | May 10, 2011, 9:00 AM | Comment!
Visit Seeking Alpha's
Company Description
Currently, there's no company description for BMTI.